Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$52.77 USD
0.00 (0.00%)
Updated Jul 31, 2025 10:20 AM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLDPF 52.77 0.00(0.00%)
Will ZLDPF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Other News for ZLDPF
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Zealand Pharma initiated with bullish view at Wells Fargo, here's why
ClearBridge International Growth ACWI Ex-US Strategy Q2 2025 Commentary
Eli Lilly Comes Out As ADA Winner
Zealand Pharma initiated with bullish view at Barclays, here's why